Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 70, Issue -, Pages 234-238Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2015.01.022
Keywords
Tramadol hydrochloride; Solid lipid nanoparticles; Polyacrylates; Drug delivery; Pain relief
Funding
- Fundacao para a Ciencia e Tecnologia do Ministerio da Ciencia e Tecnologia (FCT, Portugal) [SFRH/BD/60640/2009, SFRH/BD/80335/2011]
- European Funds [PTDC/SAU-FAR/113100/2009, FCOMP-01-0124-FEDER-022696 (PEst-C/AGR/UI4033/2011)]
- Subprograma de Proyectos de Investigacion Fundamental no Orientada del Ministerio de Ciencia e Innovacion, Spain [MAT2011-26994]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/80335/2011, SFRH/BD/60640/2009] Funding Source: FCT
Ask authors/readers for more resources
Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from the fact that they inhibit serotonin (5-HT) reuptake augmenting 5-HT concentration on the synaptic cleft. Despite this, TrHC has also been described to have several side effects which are mainly due to its fast metabolization and excretion which in turn requires multiple doses per day. To surpass this limitation, new pharmaceutical formulations are being developed intending the protection, target and sustained delivery as well as a reduction on daily dose aiming a reduction on the side effects. In the present work we have revised the efficacy, safety, biological and adverse effects of TrHC, and the added value of developing a novel drug delivery system for topical administration. (C) 2015 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available